NCT05132348 Immunophenotyping in Patients With Osteoporosis
| NCT ID | NCT05132348 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Bonn |
| Condition | Immunophenotyping Blood Samples of Patients With Osteoporosis |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2021-10-10 |
| Primary Completion | 2026-02-19 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2021-10-10 with a primary completion date of 2026-02-19.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In addition to a medical history and clinical examination, the diagnosis of osteoporosis includes the measurement of bone surface density by means of dual X-ray absorptiometry (DXA). In addition, blood tests are performed for certain parameters, such as vitamin D, calcium, phosphate and C-reactive protein. In order to optimize osteoporosis diagnostics, the development of further specific methods is required. The modulation of the immune system seems promising in this respect, since osteoporosis is based on an inflammatory reaction. Various regulatory markers of the innate and acquired immune system, which seem to be relevant in the development of the disease, have already been detected in osteoporosis patients. This study may help to gain new insights into disease-associated immunoregulatory markers that could revolutionize both the diagnosis and therapy of osteoporosis in the long term. By means of a simple blood test, patients could be diagnosed early and without additional radiation exposure, and effective therapy options could be developed.
Eligibility Criteria
Inclusion Criteria: * Adult patients (≥ 18 years) diagnosed with osteoporosis. * Written informed consent from the patient Exclusion Criteria: * Patients without diagnosed osteoporosis * Patients without written informed consent * Patients \< 18 years old * Patients with secondary osteoporosis
Contact & Investigator
Andreas Strauß, PD Dr.
PRINCIPAL INVESTIGATOR
physican
Frequently Asked Questions
Who can join the NCT05132348 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Immunophenotyping Blood Samples of Patients With Osteoporosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05132348 currently recruiting?
Yes, NCT05132348 is actively recruiting participants. Contact the research team at andreas.strauss@ukbonn.de for enrollment information.
Where is the NCT05132348 trial being conducted?
This trial is being conducted at Bonn, Germany.
Who is sponsoring the NCT05132348 clinical trial?
NCT05132348 is sponsored by University Hospital, Bonn. The principal investigator is Andreas Strauß, PD Dr. at physican. The trial plans to enroll 250 participants.